 |
answer text |
<p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines (PCV) incentivises
vaccine manufacturers and generates competition by encouraging additional manufacturers
to the market. So far, 114 million children have been vaccinated with AMC-supported
pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>The UK assess AMC to be
an effective and efficient mechanism to improve vaccine coverage at a lower cost.
It scored an A+ in its last annual review. In March 2019, Pfizer reduced the price
of PCV for 73 developing countries from US$3.30 in 2017 to US$2.90 per dose. This
further reduction is estimated to save Gavi and developing country governments up
to US$ 4.1 million.</p><p> </p><p>An independent 2015 evaluation identified AMC’s
supply arrangements as a critical factor in encouraging vaccine manufacturers to expand
their capacity to produce safe, effective vaccines. As part of the planning process
for the next phase for Gavi, the UK and other stakeholders are exploring all innovative
financing options which can improve global immunisation in poor countries.</p>
|
|
